Chimeric Therapeutics Chimeric Therapeutics aspires to be a leader in cell therapy and to develop life-changing medicines for humankind We put patients first We demonstrate compassion and kindness to our patients and their families We strive to do the right thing Our people are our greatest assets We are intellectually curious Our science is data driven We are collaborative We value relationships based on trust and integrity We will be good stewards of our investors’ capital We will admit our mistakes and seek to learn from them We aim to have fun The value of our output must be worth more than the inputs
Chimeric Therapeutics - Clinical milestones for 2024 & 2023 successes highlighted 14/03/2024 09:58:00 -- Reported positive preliminary data for CHM 1101 in heavily pretreated glioblastoma patients, confirming advancement to next phase of CHM 1101 development -- FDA IND clearance for CHM 2101 enabli…
Chimeric Therapeutics - Half Yearly Report and Accounts 29/02/2024 08:19:00 To view the report, download the attached PDF.
Chimeric Therapeutics - 1st patient treated in ADVENT-AML Phase 1b clinical trial 08/02/2024 09:22:00 ADVENT-AML is the first clinical trial to evaluate NK cell therapy in combination with the current standard of care for Acute Myeloid Leukemia (AML) patients The trial, no…